TW200511999A - Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone - Google Patents
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormoneInfo
- Publication number
- TW200511999A TW200511999A TW093128228A TW93128228A TW200511999A TW 200511999 A TW200511999 A TW 200511999A TW 093128228 A TW093128228 A TW 093128228A TW 93128228 A TW93128228 A TW 93128228A TW 200511999 A TW200511999 A TW 200511999A
- Authority
- TW
- Taiwan
- Prior art keywords
- methods
- pharmaceutical compositions
- parathyroid hormone
- vitamin
- alkylidene
- Prior art date
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 3
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000199 parathyroid hormone Substances 0.000 title abstract 3
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000011612 calcitriol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50450303P | 2003-09-19 | 2003-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200511999A true TW200511999A (en) | 2005-04-01 |
Family
ID=34375509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093128228A TW200511999A (en) | 2003-09-19 | 2004-09-17 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050065088A1 (zh) |
EP (1) | EP1667689A1 (zh) |
JP (1) | JP2007505883A (zh) |
KR (1) | KR20060058133A (zh) |
CN (1) | CN1852716A (zh) |
AU (1) | AU2004273660B2 (zh) |
BR (1) | BRPI0414518A (zh) |
CA (1) | CA2539357A1 (zh) |
IL (1) | IL174144A0 (zh) |
MX (1) | MXPA06003064A (zh) |
NO (1) | NO20061236L (zh) |
NZ (1) | NZ545803A (zh) |
RU (1) | RU2006108557A (zh) |
TW (1) | TW200511999A (zh) |
WO (1) | WO2005027915A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122533B2 (en) * | 1999-11-29 | 2006-10-17 | The United States Of America As Represented By The Department Of Health And Human Services | Cosalane compounds and methods for their use |
JP2007512376A (ja) | 2003-11-25 | 2007-05-17 | ウイスコンシン アラムニ リサーチ ファンデーション | 肥満症の予防及び治療用ビタミンd類似体 |
JP2007512371A (ja) * | 2003-11-25 | 2007-05-17 | デルタノイド ファーマシューティカルズ,インコーポレイティド | ビタミン化合物を用いる体脂肪の減少方法 |
US7563783B2 (en) * | 2005-02-11 | 2009-07-21 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2 |
ATE554774T1 (de) * | 2005-02-11 | 2012-05-15 | Wisconsin Alumni Res Found | 2-methylen-19-nor-(20s-24epi)-1alpha,25- dihydrovitamin-d2 |
CA2603328A1 (en) * | 2005-03-29 | 2006-10-05 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(23s)-25-dehydro-1.alpha.-hydroxyvitamin d3-26,23-lactone and 2-methylene-19-nor-(23r)-25-dehydro-1.alpha.-hydroxyvitamin d3-26,23-lactone |
CA2793727C (en) * | 2010-03-23 | 2017-01-03 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1.alpha.,25-dihydroxyvitamin d3 |
US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
ES2545403T3 (es) | 2010-03-23 | 2015-09-10 | Wisconsin Alumni Research Foundation | (20S)-2-metilen-19-nor-22-dimetil-1alfa,25-dihidroxivitamina D3 y (20R)-2-metilen-19-nor-22-dimetil-1alfa,25-hidroxivitamina D3 |
WO2015050160A1 (ja) * | 2013-10-03 | 2015-04-09 | 国立大学法人大阪大学 | 副甲状腺ホルモンまたはその誘導体を有効成分とする筋の老化防止用医薬組成物 |
WO2015064585A1 (ja) * | 2013-10-29 | 2015-05-07 | 国立大学法人熊本大学 | 筋疾患の治療または予防のための医薬組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | 2−位に置換基を有する19−ノル−ビタミンd3 化合物 |
US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
DZ2873A1 (fr) * | 1998-08-19 | 2003-12-15 | Lilly Co Eli | Procédé pour augmenter la dureté et la rigidité osseuse. |
SI1059933T1 (en) * | 1998-08-19 | 2003-04-30 | Eli Lilly & Company | Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture |
-
2004
- 2004-09-06 BR BRPI0414518-6A patent/BRPI0414518A/pt not_active IP Right Cessation
- 2004-09-06 JP JP2006526715A patent/JP2007505883A/ja active Pending
- 2004-09-06 WO PCT/IB2004/002902 patent/WO2005027915A1/en active Application Filing
- 2004-09-06 EP EP04769301A patent/EP1667689A1/en not_active Withdrawn
- 2004-09-06 NZ NZ545803A patent/NZ545803A/en unknown
- 2004-09-06 KR KR1020067005457A patent/KR20060058133A/ko not_active Application Discontinuation
- 2004-09-06 CA CA002539357A patent/CA2539357A1/en not_active Abandoned
- 2004-09-06 CN CNA2004800268486A patent/CN1852716A/zh active Pending
- 2004-09-06 AU AU2004273660A patent/AU2004273660B2/en not_active Expired - Fee Related
- 2004-09-06 RU RU2006108557/15A patent/RU2006108557A/ru not_active Application Discontinuation
- 2004-09-06 MX MXPA06003064A patent/MXPA06003064A/es unknown
- 2004-09-16 US US10/946,585 patent/US20050065088A1/en not_active Abandoned
- 2004-09-17 TW TW093128228A patent/TW200511999A/zh unknown
-
2006
- 2006-03-06 IL IL174144A patent/IL174144A0/en unknown
- 2006-03-17 NO NO20061236A patent/NO20061236L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060058133A (ko) | 2006-05-29 |
AU2004273660A1 (en) | 2005-03-31 |
WO2005027915A1 (en) | 2005-03-31 |
NZ545803A (en) | 2008-03-28 |
CA2539357A1 (en) | 2005-03-31 |
JP2007505883A (ja) | 2007-03-15 |
US20050065088A1 (en) | 2005-03-24 |
NO20061236L (no) | 2006-06-15 |
EP1667689A1 (en) | 2006-06-14 |
RU2006108557A (ru) | 2007-09-27 |
CN1852716A (zh) | 2006-10-25 |
BRPI0414518A (pt) | 2006-11-07 |
MXPA06003064A (es) | 2006-05-31 |
IL174144A0 (en) | 2006-08-01 |
AU2004273660B2 (en) | 2010-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1558220A4 (en) | ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
MX2010002498A (es) | Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol. | |
TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
AU2003301190A1 (en) | Administration of capsaicinoids | |
MXPA04008068A (es) | Metodo para administrar moleculas de glp-1. | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
MXPA05006670A (es) | Administracion de capsaicinoides. | |
WO2004021968A3 (en) | Solution for ungual application | |
WO2004043341A3 (en) | Treatment for hemorrhagic shock | |
NO20061236L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton | |
BRPI0414565A (pt) | composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato | |
MXPA05005338A (es) | Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas. | |
WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
HK1081861A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
GB2446341A (en) | Method and system for transdermal drug delivery | |
TW200500079A (en) | Compositions and methods for treating coronavirus infection and sars | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
PT1656131E (pt) | Utilização de betaína para tratar claudicação intermitente | |
WO2004110373A3 (en) | Therapeutic vaccine compositions for the treatment of type 1 diabetes | |
NO20054034L (no) | Fremgangsmate for behandling av hypotyroidisme. | |
HK1111924A1 (en) | Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient | |
SE0203817D0 (sv) | New composition | |
IL174134A0 (en) | Use of a protein in the preparation of a medicament for treatment of fibrotic diseases | |
WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
WO2006091222A3 (en) | Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118 |